title: Reply to the comment by Skrobik et al.
authors.forename: Sophia
authors.initials: S
authors.lastname: de Rooij
authors.forename: Evert
authors.initials: E
authors.lastname: de Jonge
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D016638:Critical Illness; D003693:Delirium / Q000188:drug therapy*; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000077152:Olanzapine; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D006220:Haloperidol; D000077152:Olanzapine